Literature DB >> 10229016

Early detection of liposome brain localization in rat experimental allergic encephalomyelitis.

V Rousseau1, B Denizot, J J Le Jeune, P Jallet.   

Abstract

Blood-brain barrier (BBB) permeability increases prior to the development of clinical signs in early-stage multiple sclerosis (MS). Detection of subtle changes would thus be helpful for diagnostic purposes and rapid therapeutic decisions before new episodes. Since multiple sclerosis and experimental allergic encephalomyelitis (EAE) have numerous common features, in particular BBB-permeability characteristics, and since we have previously shown that BBB localization is disturbed by tumors, embolism, and mannitol injection, we investigated BBB-liposome permeability in an EAE rat model. Twenty young male Lewis rats received a single intradermal inoculation of guinea-pig spinal cord. The effect of the Freund's adjuvant and spinal cord alone on brain permeability were also assessed. In order to compare solution permeability and liposome localization, radioactive liposomes and, 1 h later, 99mTc-DTPA were injected intravenously. Scintigraphic acquisitions were obtained to follow the biodistribution of radioactivity in the whole body. Each rat was subjected to a first examination before inoculation and then every two days until completion and may be considered as its own control. EAE induced a previously unreported increase in global-body permeability, probably due to inflammation. Liposome brain localization and brain/heart ratio were significantly different between normal animals and those with early-stage EAE (before appearance of clinical signs) and distinguished between different disease stages in clinically patent EAE. The index of disease progression was modified earlier than with 99mTc-DTPA injection. One explanation may be particle pick-up by circulating macrophages, which cross the BBB during this pathology. For clinical applications, experiments must be confirmed on models more reliable for human multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229016     DOI: 10.1007/s002210050681

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  10 in total

1.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

2.  Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue.

Authors:  R M Schiffelers; G Storm; I A Bakker-Woudenberg
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

3.  A macrophage-nanozyme delivery system for Parkinson's disease.

Authors:  Elena V Batrakova; Shu Li; Ashley D Reynolds; R Lee Mosley; Tatiana K Bronich; Alexander V Kabanov; Howard E Gendelman
Journal:  Bioconjug Chem       Date:  2007-08-31       Impact factor: 4.774

4.  Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension.

Authors:  Gavin Wright; Debbie Shawcross; Steven W M Olde Damink; Rajiv Jalan
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

Review 5.  PART 2: Mouse models for multiple sclerosis research.

Authors:  Ramalakshmi Ramasamy; Phillip P Smith
Journal:  Neurourol Urodyn       Date:  2021-03-19       Impact factor: 2.696

6.  Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids.

Authors:  Yuval Avnir; Keren Turjeman; Deborah Tulchinsky; Alex Sigal; Pablo Kizelsztein; Dina Tzemach; Alberto Gabizon; Yechezkel Barenholz
Journal:  PLoS One       Date:  2011-10-06       Impact factor: 3.240

Review 7.  Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine.

Authors:  Francis Man; Peter J Gawne; Rafael T M de Rosales
Journal:  Adv Drug Deliv Rev       Date:  2019-06-03       Impact factor: 15.470

Review 8.  Targeting Fibronectin to Overcome Remyelination Failure in Multiple Sclerosis: The Need for Brain- and Lesion-Targeted Drug Delivery.

Authors:  Pauline E M van Schaik; Inge S Zuhorn; Wia Baron
Journal:  Int J Mol Sci       Date:  2022-07-29       Impact factor: 6.208

9.  Revolutionary impact of nanodrug delivery on neuroscience.

Authors:  Reza Khanbabaie; Mohsen Jahanshahi
Journal:  Curr Neuropharmacol       Date:  2012-12       Impact factor: 7.363

Review 10.  Targeting sites of inflammation: intercellular adhesion molecule-1 as a target for novel inflammatory therapies.

Authors:  Susan Hua
Journal:  Front Pharmacol       Date:  2013-10-04       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.